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Sepsis is an unmet clinical need constituting one of the most important causes of death 
worldwide, a fact aggravated by the appearance of multidrug resistant strains due to 
indiscriminate use of antibiotics. Host innate immune receptors involved in pathogen- 
associated molecular patterns (PAMPs) recognition represent a source of broad-spectrum 
therapies alternative or adjunctive to antibiotics. Among the few members of the ancient 
and highly conserved scavenger receptor cysteine-rich superfamily (SRCR-SF) sharing 
bacterial-binding properties there is CD6, a lymphocyte-specific surface receptor. Here, 
we analyze the bacterial-binding properties of three conserved short peptides (11-mer) 
mapping at extracellular SRCR domains of human CD6 (CD6.PD1, GTVEVRLEASW; 
CD6.PD2 GRVEMLEHGEW; and CD6.PD3, GQVEVHFRGVW). All peptides show high 
binding affinity for PAMPs from Gram-negative (lipopolysaccharide; Kd from 3.5 to 
3,000 nM) and Gram-positive (lipoteichoic acid; Kd from 36 to 680 nM) bacteria. The 
CD6.PD3 peptide possesses broad bacterial-agglutination properties and improved 
survival of mice undergoing polymicrobial sepsis in a dose- and time-dependent manner. 
Accordingly, CD6.PD3 triggers a decrease in serum levels of both pro-inflammatory cyto-
kines and bacterial load. Interestingly, CD6.PD3 shows additive survival effects on septic 
mice when combined with Imipenem/Cilastatin. These results illustrate the therapeutic 
potential of peptides retaining the bacterial-binding properties of native CD6.
Keywords: bacteria, cD6, cecal ligation and puncture, infection, peptide interaction, scavenger receptor, sepsis, 
imipenem/cilastatin
inTrODUcTiOn
Sepsis is a common and life-threatening disease worldwide causing organ dysfunction as a consequence 
of dysregulated host inflammatory response to an infection (mainly bacterial) (1). Its more deadly 
form is septic shock, in which profound circulatory, cellular, and metabolic abnormalities are associ-
ated with a greater risk of mortality, particularly for the elderly and the immunocompromised (2, 3). 
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Despite advances in supportive care and availability of potent 
broad-spectrum antibiotics, the incidence and severity of sepsis 
and septic shock have been rising steadily as a result of population 
aging, invasive medical procedures, chronic disease prevalence, 
and emergence of multidrug resistant (MDR) bugs (1, 3). Sepsis 
remains an unmet clinical need of complex pathophysiology, 
calling for urgent innovative developments on cost-effective 
biological treatments and/or medical devices, alternative or 
complementary to antibiotics and supportive care (4).
Adjunctive/alternative therapies to antibiotics include host-
directed approaches addressed to potentiate the innate defense 
mechanisms and/or reverse the immune cell dysfunction associ-
ated with sepsis mortality (5). The neutralization of pathogenic 
microbial factors with endogenous host immune constituents 
represents one such approach. In this regard, some members of 
the ancient and conserved scavenger receptor cysteine-rich super-
family (SRCR-SF) interact with pathogen-associated molecular 
patterns (PAMPs) both from Gram-negative (lipopolysaccharide, 
LPS) or Gram-positive (lipoteichoic acid, LTA and peptidoglycan, 
PGN) bacteria (6). PAMPs are constitutive components of bacte-
rial walls, absent from the host, and essential for bacterial survival 
and pathogenicity (7). PAMPs are crucial for bacterial viability 
and virulence and have remained conserved through evolution 
The prototypical member of the SRCR-SF displaying bacterial 
PAMPs binding properties is deleted in malignant brain tumors-1 
(DMBT-1), also known as salivary agglutinin (SAG) or gp340 
(8, 9). DMBT-1/SAG is a soluble glycoprotein containing 14 SRCR, 
one zona pellucida, and two C1r/C1s Uegf Bmp1 domains. The 
bacterial-binding properties of DMBT-1/SAG have been accu-
rately mapped within its SRCR domains to an 11-mer consensus 
peptide sequence (DMBT-1/SAG.pbs1, GRVEVLYRGSW) from 
which a 9-mer motif (VEVLxxxxW) present in 13 out 14 of them 
was identified (10). Other SRCR-SF members with bacterial-
binding properties include the following: Class A macrophage 
scavenger receptor type I (11), macrophage receptor with col-
lagenous structure (MARCO) (12), soluble protein α (13), CD6 
(14), CD163 (15), scavenger receptor class A member 5 (16), and 
soluble scavenger receptor cysteine-rich group B member with 
five domains (17, 18). The bacterial-binding regions of these 
peptides have only been functionally mapped for MARCO (12) 
and CD163 (15).
CD6 is a lymphocyte surface glycoprotein expressed by all 
T cells and a subset of B and NK cells (19). Functionally, CD6 is a 
signal-transducing receptor involved in lymphocyte activation and 
differentiation upon adhesive contacts with antigen-presenting 
cells expressing the CD6 ligand—CD166/activated leukocyte cell 
adhesion molecule (ALCAM) (20)—or other recently reported 
counterreceptors such as Galectins (21) and CD318 (22). 
Structurally, CD6 belongs to the SRCR-SF owing to the three 
tandem SRCR repeats in its ectodomain. Previous work by our 
group demonstrated that the recombinant soluble human CD6 
ectodomain (rshCD6) binds to and agglutinates Gram-positive 
and Gram-negative bacteria in  vitro. In vivo, rshCD6 infusion 
protects mice from septic shock induced by mono- and poly-
microbial models of peritonitis (14, 23, 24). Binding of rshCD6 
to bacterial PAMPs such as LPS, LTA, or PGN takes place with 
Kd affinities in the nM range, similar to CD14’s binding affinity 
to the same PAMPs (25, 26). Moreover, rshCD6 downmodulates 
the pro-inflammatory cytokine (IL-1β, IL-6, and TNF-α) release 
triggered by LPS or LTA/PGN (23). In light of this evidence, the 
bacterial-binding properties of CD6-derived peptide sequences 
(CD6.PD1, CD6.PD2, and CD6.PD3) homologous to the 11-mer 
consensus peptide previously reported in DMBT-1/SAG (pbs1) 
were investigated. Our in  vitro and in  vivo results support the 
therapeutic potential of these peptide sequences, with varying 
degrees of bacterial agglutination and PAMP binding potential, 
and demonstrate a protective role in cecal ligation and puncture 
(CLP)-induced polymicrobial peritonitis (27).
MaTerials anD MeThODs
Production and Purification of 
recombinant Proteins and Peptides
Recombinant soluble human CD6 ectodomain and rshCD5 
proteins were purified following the reported methods (28) 
using SURE CHO-M Cell line™ clones (Selexis SUREtechnology 
Platform™, Geneva, Switzerland) and size-exclusion chromatog-
raphy protocols developed at PX’Therapeutics (Grenoble, France). 
Human and bovine seroalbumin (BSA) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Peptides (>80% purity) 
were manufactured by ProteoGenix (Schiltigheim, France) and 
stocked at 5 mg/mL with diluted (1:3) acetonitrile.
Bacterial agglutination assays
5 × 108 colony-forming units (CFU)/mL diluted in TTC buffer 
(50 mM Tris pH 7.5 plus 150 mM NaCl, 0.1% Tween 20, and 1 mM 
Ca2+) were mixed (1:1) with different peptide concentrations 
(0–200 µg/mL) in 96 U-bottomed well microtiter plates (Biofil) 
(29). After overnight incubation at 37°C, bacterial agglutination 
was examined by light microscopy and scored from − (absent) to 
+ + + (maximal).
Bacterial strains
Multidrug-resistant Acinetobacter baumannii clinical isolate, 
Enterobacter cloacae ATCC 23355, Escherichia coli ATCC 25922, 
Klebsiella pneumoniae ATCC 13883, Listeria monocytogenes ATCC 
19111, Pseudomonas aeruginosa ATCC 27853, Staphylococcus 
aureus ATCC 25923, and Methicillin-resistant S. aureus (MRSA) 
clinical isolate were provided by Dr. Jordi Vila (Microbiology 
Department, Hospital Clinic of Barcelona) and grown in Luria 
Bertani or agar with 5% sheep blood (Becton Dickinson) at 37°C, 




To explore the ability of different peptides/proteins to bind LTA 
(Mr = 14,000, from S. aureus; Sigma) and rough LPS (Re-LPS, 
Mr = 2,500, from Salmonella minnesota serotype Re 595; Sigma), 
binding studies were carried out in an AB2 spectrofluorometer 
with a thermostated cuvette holder (±0.1°C), using 5 mm × 5 mm 
path length quartz cuvettes as described (30). Re-LPS concentra-
tion was assessed by quantification of 2-keto-3-deoxyoctulosonic 
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acid (31). Peptide/protein samples (10 µg/mL) were titrated with 
different amounts of a stock solution of either LTA or Re-LPS in 
phosphate buffered saline (PBS) pH 7.2, and the Trp fluorescence 
emission spectra recorded with excitation at 295 nm. The fluo-
rescence intensity readings were corrected for the dilution caused 
by peptide/protein addition. Background intensities in peptide/
protein-free samples due to LTA or Re-PS were subtracted from 
each recording. The apparent dissociation constant (Kd) of 
peptide/protein–ligand complexes were obtained by non-linear 
least-squares fitting to the Hill equation of the change in peptide 
fluorescence at 353 nm with the amount of added LTA or Re-LPS 
(31): ΔF/ΔFmax  =  [L]n/([L]n  +  Kd), where ΔF is the change in 
fluorescence intensity at 353 nm relative to the intensity of free 
peptide; ΔFmax is the change in fluorescence intensity at saturating 
LTA or Re-LPS concentrations; [L] is the molar concentration of 
free ligand; and n is the Hill coefficient.
Solid Phase Binding Assays
96-well microtiter plates (Nunc, Roskilde, Denmark) were coated 
overnight at 4°C with 5  µg/mL of purified LPS (from E. coli 
O111:B4, Sigma L2630) or LTA (from S. aureus, Sigma L2515) 
in PBS and then incubated for 2 h at room temperature in block-
ing solution (20 mM Tris-HCl pH 7.4 plus 0.05% Tween 20 and 
1% BSA). Biotin-labeled peptides/proteins (2.5–20 µg/mL) were 
added and incubated overnight at 4°C in blocking solution. After 
extensive washing, bound peptides/proteins were detected by the 
addition of horseradish peroxidase-labeled streptavidin (1:5,000 
dilution; DAKO) for 1 h at room temperature. Color was devel-
oped by adding 3,3’,5,5’-tetramethylbenzidine liquid substrate 
(Sigma) and optical density read at 405–620 nm.
Dynamic light scattering (Dls)
The hydrodynamic diameters of peptides (10  µg/mL in PBS) 
were measured at 25°C in a Zetasizer Nano S from Malvern 
Instruments (Worcestershire, UK) equipped with a 633 nm HeNe 
laser, as described (32). Four scans were recorded for each sample, 
and the samples were analyzed in triplicate.
In Vitro cell cultures
Spleens from 6- to 8-week-old C57BL/6 mice (Charles River) 
were disaggregated by filtering through a cell strainer and, after 
erythrocyte lysis, the cells were resuspended in RPMI 1640 
with l-glutamine (Lonza) plus 10% fetal calf serum (BioWest), 
100  U/mL penicillin, 100  µg/mL streptomycin, and 50  µM 
2-β-mercaptoethanol (Merck). Cells (2  ×  105) were stimulated 
for 48 h (at 37°C in a humidified atmosphere with 5% CO2) in 
U-bottomed 96-well plates (Biofil) containing LPS (0.5 µg/mL; 
E. coli O111:B4), in the presence or absence of increasing peptides 
(0.5–20 µg/mL). Culture supernatants were harvested and mouse 
cytokines measured by ELISA following manufacturer’s instruc-
tions (BD Biosciences OptEIA sets).
clP Procedure
Animal procedures were approved by the Animal Experimentation 
Ethical Committee, University of Barcelona. High-grade mortality 
(≥90% mortality within the first 48–72  h) CLP-induced septic 
shock was induced in 8- to 10-week-old C57BL/6J male mice 
(20–25 g; Charles River) as previously reported (24).
For the assessment of bacterial load, blood and spleen samples 
from CLP-treated mice were collected, homogenized, and diluted 
aseptically in sterile PBS. Serial dilutions were plated overnight 
on agar with 5% sheep blood (Becton Dickinson) at 37°C. Viable 
bacterial counts were expressed as CFU/mL (blood) or per mg 
(spleen).
statistical analysis
Survival assays were analyzed by a log-rank χ2 test using GraphPad 
Prism software. The significance of differences between experi-
mental groups was determined by two-tailed paired t test with 
95% confidence interval (CI). P values were considered significant 
when P < 0.05. Statistical analysis (mean ± SEM) was performed 
using a two-tailed Mann–Whitney test, with 95% CI.
resUlTs
induction of Bacterial agglutination  
by cD6-Derived Peptides
To investigate the bacterial-binding properties of CD6, intrado-
main peptide sequences homologous to the consensus 11-mer 
DMBT-1/SAG.pbs1 peptide sequence (GRVEVLYRGSW) (10) 
were synthesized. The sequence and physicochemical properties 
of such CD6-derived peptides mapping at SRCR domains 1–3 
(CD6.PD1, CD6.PD2, and CD6.PD3, respectively), as well as of 
the other peptides and proteins used in this study are compiled 
in Figure 1A. Structural analyses depicted in Figure 1B showed 
that all CD6 peptides are accessible at the surface of CD6, with 
CD6.PD1 (and CD6.PD3) being exposed at opposing sides from 
that of CD6.PD2. Interestingly, CD6.PD3 mapped at a distant 
position of the amino acids involved in CD6 binding to CD166/
ALCAM (20) (Figure 1B). As illustrated in Figure 1C, the amino 
acid conservation of the CD6-derived peptides among different 
animal species was relatively high for CD6.PD2 and CD6.PD3 
and lower for CD6.PD1.
None of the CD6-derived peptides matched the minimal 
9-mer DMBT-1/SAG.pbs1 consensus motif (VEVLxxxxW)—a 
fact also shared by the CD163p2 (GRIEIKFQRRW) peptide 
(15)—and function was explored in bacterial agglutination 
assays. The DMBT-1/SAG.pbs1 peptide was used as positive 
control (10), and the analogous peptide sequence (CD5.PD2) 
present in the second SRCR domain of CD5—a highly homolo-
gous lymphocyte receptor for which no bacterial binding 
properties have been reported—used as negative control. As 
illustrated by Figures  2A,B, dose-dependent agglutination of 
different Gram-positive and Gram-negative bacterial suspen-
sions (including MDR strains) was observed for CD6.PD1 and 
CD6.PD3, but not for CD6.PD2. These results indicate that 
some but not all CD6-derived sequences retain the bacterial 
agglutination properties of native CD6 (14) and DMBT-1/SAG 
proteins and of pbs1 (10, 29).
FigUre 1 | Structural characteristics of the peptides and proteins from the scavenger receptor cysteine-rich superfamily (SRCR-SF) members in the study.  
(a) Amino acid sequence, molecular weight (M.W.) and isoelectric point (pI) of the CD5, CD6, and deleted in malignant brain tumors-1 (DMBT-1) peptides and 
proteins analyzed in this study. (B) Three-dimensional surface representations of the extracellular region of human CD6 (PDB identifier 5a2e, visualized with Jmol) 
displaying the relative position of the CD6 peptides in the study (colored red) and amino acids involved in binding to the CD6 ligand, CD166/activated leukocyte cell 
adhesion molecule (ALCAM) (colored blue). (c) Alignment of the SRCR domain 1, 2, and 3 amino acid sequences of CD6 from primate (Homo sapiens, accession 
number P30203; Pan troglodytes, H2Q3T6; Nomascus leucogenys, G1RTX7; Macaca mulatta, H9ZFC2; and Tarsius syrichta, A0A1U7SL56) rodent (Mus 
musculus, Q61003; Rattus norvegicus, Q812A4; and Mesocricetus auratus, A0A1U8BJ49), lagomorph (Oryctolagus cuniculus, G1T3D3), artiodactyl (Bos taurus, 
F1MU15; Sus scrofa, K7GS39), carnivoran (Canis lupus familiaris, F1PV91; Felis silvestris catus, M3WJ99), crocodilian (Alligator mississippiensis, A0A151NXS4), 
and fish (Poeciliopsis prolifica, A0A0S7G288; Salmo salar, A0A1S3RVR2) species, where the peptides in study (colored yellow) map. Conserved intradomain 
cysteine residues and amino acid identities are highlighted in green and blue, respectively.
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cD6-Derived Peptides Directly interact 
With PaMPs constitutive of  
gram-negative and gram-Positive 
Bacteria With Different affinities
Absence of bacterial agglutination does not fully exclude 
direct binding to bacterial PAMPs, so binding of biotin-labeled 
CD6-derived peptides to solid-phase bound LPS or LTA was 
tested by ELISA. As shown by Figures 3A,B, all CD6-derived 
peptides showed dose-dependent binding to LPS and LTA, 
similar to the pbs1 peptide and rshCD6 protein used as positive 
controls. As expected, no significant binding was observed for 
the CD5.PD1 peptide and the rshCD5 protein. These results 
confirm that CD6-derived peptides retain binding properties to 
FigUre 2 | Bacterial agglutination properties of CD6-derived peptides. Increasing concentrations (5, 50, and 200 µg/mL) of the indicated CD6 (PD1, PD2, and 
PD3), deleted in malignant brain tumors-1 (DMBT-1) (pbs1; C+), and CD5 (PD2; C−)-derived peptides were incubated for 2 h at room temperature in 96-well 
U-bottomed plates with alive bacterial cell suspensions [75 × 106 colony-forming units (CFU)/mL] in TTC buffer. Bacterial agglutination was scored and consensed 
by two independent observers as −, ±, +, + +, or +++. (a) Summary of the agglutination results obtained with the indicated panel of Gram-negative (multidrug-
resistant Acinetobacter baumannii clinical isolate; Enterobacter cloacae ATCC 23355; Escherichia coli ATCC 25922; Klebsiella pneumoniae ATCC 13883; Listeria 
monocytogenes ATCC 19111; and Pseudomonas aeruginosa ATCC 27853) and Gram-positive [Staphylococcus aureus ATCC 25923; methicillin-resistant S. aureus 
(MRSA) clinical isolate] bacterial strains. (B) Representative agglutination results obtained for the MRSA clinical isolate.
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FigUre 3 | Analysis of the direct binding characteristics of CD6-derived peptides to purified pathogen-associated molecular patterns (PAMPs) from Gram-negative 
and Gram-positive origin. Increasing concentrations (5–20 µg/mL) of biotin-labeled CD6 (PD1, PD2, and PD3), deleted in malignant brain tumors-1 (DMBT-1)/
SAG- (pbs1), and CD5- (PD1) derived peptides (top panel), or rshCD5 and recombinant soluble human CD6 ectodomain (rshCD6) proteins (bottom panel) were 
added to 96-well ELISA plates sensitized with lipopolysaccharide (LPS) (a) or lipoteichoic acid (LTA) (B). Following overnight incubation at 4°C bound peptides or 
proteins were developed by addition of horseradish peroxidase–streptavidin and 3,3’,5,5’-tetramethylbenzidine substrate and further readings at OD 405–620 nm. 
Results are expressed as mean ± SD of duplicates from one representative experiment of three performed. Statistical analysis was performed by two-way ANOVA 
(*P < 0.05; **P < 0.01; and ***P < 0.001). (c) Apparent Kd values and Hill coefficients for the binding of peptides and proteins in study to LPS and LTA determined 
by tryptophan fluorescence. Peptides and proteins (10 µg/mL) were titrated with or without increasing concentrations of LPS or LTA in phosphate buffered saline 
(PBS). Results are mean ± SD of three experiments. (D) Dynamic light scattering analysis of the hydrodynamic diameter of CD6 (PD1, PD2, and PD3) and DMBT-1/
SAG (pbs1)-derived peptides (10 µg/mL) in PBS. The y axis represents the relative intensity of the scattered light; the x axis denotes the hydrodynamic diameter of 
the particles present in the solution. One representative experiment of four is shown.
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LPS and LTA as reported for native CD6 but not CD5 proteins 
(14, 23).
To further characterize the interaction of CD6-derived pep-
tides with LPS and LTA, the corresponding dissociation constants 
(Kd) were determined by tryptophan fluorescence emission. As 
summarized in Figure 3C (Figure S1 in Supplementary Material), 
all CD6-derived peptides displayed high affinities for both LPS 
and LTA, being higher for CD6.PD1 and/or CD6.PD2 compared 
to CD6.PD3 (PD1 ≥ PD2 > PD3). Kd values for CD6.PD1 and 
CD6.PD2, but not CD6.PD3, are lower than for the prototypical 
DMBT-1/SAG.pbs1 peptide or the rshCD6 protein itself. The 
greater affinity of CD6.PD1 and CD6.PD2 for LPS, and LTA is not 
correlated with their bacterial agglutination properties, which are 
absent in CD6.PD2.
To determine whether self-aggregation properties of CD6-
derived peptides are related to their agglutination properties, 
FigUre 4 | Effect of CD6-derived peptides on bacterial lipopolysaccharide 
(LPS)-induced cytokine release in vitro by mouse splenocytes. Total spleen 
cell suspension (2 × 105) from C57BL/6 mice (n = 7) was stimulated in 
triplicate for 48 h with LPS (0.5 µg/mL), in the presence or absence of 
increasing concentrations (0.5, 5, and 20 µg/mL) of CD6-derived peptides 
(PD1, PD2, and PD3). Cytokine levels in culture supernatants were 
determined by ELISA and results expressed in pg/mL as mean ± SD of 
triplicates. Viability was >75% at 48 h in all experimental conditions. 
Statistical analysis was performed using a two-tailed Mann–Whitney test, 
with confidence intervals of 95% (n.s., not significant; *P < 0.05; **P < 0.01; 
and ***P < 0.001).
7
Martínez-Florensa et al. Bacterial-Binding CD6 Peptides and Sepsis
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 627
the hydrodynamic size of CD6-derived peptides in solution was 
analyzed by DLS. Results indicate that CD6-derived peptides 
formed particles of different hydrodynamic sizes according to 
their self-aggregation properties (Figure 3D). CD6.PD3 parti-
cles exhibited two peaks, at 630 ± 3 and 5.151 ± 7 nm, indicative 
of self-aggregation. In contrast, CD6.PD2 showed a single peak 
centered at 379 ± 5 nm, whereas CD6.PD1 showed two peaks 
at 321  ±  5 and 1.484  ±  8  nm, in line with the greater bacte-
rial agglutination properties of CD6.PD3 (and CD6.PD1) with 
respect to CD6.PD2. Higher CD6.PD3 binding to immobilized 
LPS or LTA (Figures 3A,B) may respond to the fact that self-
association of biotinylated peptide would produce an enhance-
ment of the chromogenic signal. Whatever the case, the binding 
results univocally support the direct and substantial interaction 
of CD6-derived peptides with essential cell wall components 
from Gram-negative and Gram-positive bacterial strains.
Next, the functional relevance of CD6-derived peptides inter-
action with key pathogenic bacterial products was explored ex 
vivo. To this end, the modulatory effects of increasing concentra-
tions of CD6-peptides on cytokine release by mouse splenocytes 
exposed to LPS were tested. As illustrated by Figure  4, only 
CD6.PD3 showed significant dose-dependent inhibitory effects 
on pro-inflammatory IL-6 and IL-1β cytokine release, which 
reached statistical significance in the former case. The same 
CD6.PD3 peptide also induced a non-statistically significant 
increased release of the anti-inflammatory cytokine IL-10, as 
reported for rshCD6 (23). No significant effect was observed 
regarding TNF-α release for any of the CD6-derived peptides 
tested (data not shown).
In Vivo efficacy of cD6-Derived Peptides 
in clP-induced septic shock
The effects of CD6-derived peptides in vivo were tested in mice 
undergoing CLP-induced septic shock (27). To this end, a single 
intravenous (i.v.) dose (6  mg/kg) of the different CD6-derived 
peptides was infused to C57BL/6 mice 1 h post CLP-induction, 
and survival monitored thereafter. As shown in Figure  5, 
increased survival was observed among mice infused with CD6.
PD2 (12.5%, P  =  0.0005) and CD6.PD3 (36.36%, P  <  0.0001) 
compared to the saline-treated group, a fact also observed in 
mice infused with the DMBT-1/SAG.pbs1 (23.07%, P = 0.0025). 
In contrast, no effects were evidenced for CD6.PD1.
Since the in  vivo protective properties of CD6.PD3 against 
septic shock excelled CD6.PD1 and CD6.PD2, additional experi-
ments exploring its time-, dose-, and systemic via-dependent 
effects were performed. As shown in Figures  6A–C, maximal 
survival rates post CLP were obtained following CD6.PD3 infu-
sion at 6 or 12 mg/kg doses (37.5 and 40%, respectively, vs 23.08% 
at 3 mg/kg), and 1 h after CLP induction (40% at + 1 h vs 20% 
at + 3 h), irrespective of the i.v. or intraperitoneal (i.p.) infusion 
pathway used.
Next, the effect of the CD6.PD3 peptide on serum cytokine 
levels and bacterial load post CLP were further monitored. To this 
end, C57BL/6 mice undergoing CLP-induced septic shock were 
treated with saline or CD6.PD3 peptide under the previously 
stated optimal conditions (single i.v. infusion of 6 mg/kg at 1 h 
post CLP) and thereafter bled and sacrificed at 4 and 20 h later, 
respectively.
As shown in Figure  7A, CD6.PD3-treated mice exhibited 
lower levels (P < 0.05) of the pro-inflammatory cytokines IL-1β, 
IL-6, and TNF-α at 20 h post CLP, compared to the saline-treated 
group. Similarly, the same CD6.PD3-treated mice also produced 
lower CFU isolated from blood and spleen when sacrificed at 
20 h post CLP, compared to the control group (Figure 7B). These 
results indicate that the CD6.PD3 peptide retains the therapeutic 
properties reported for the rshCD6 protein in experimental 
FigUre 6 | Analysis of dose-, time-, and via-dependent effects of CD6.PD3 
infusion on mouse survival following cecal ligation and puncture (CLP)-
induced sepsis. (a) C57BL/6 mice were intravenous (i.v.) infused 1 h post 
CLP with saline (n = 26) or single increasing doses (3 mg/kg, n = 13; 6 mg/kg, 
n = 15; and 12 mg/kg, n = 8) of unlabeled CD6.PD3 peptide. (B) C57BL/6 
mice were i.v. infused with saline (n = 5) or 6 mg/kg CD6.PD3 at different 
times post CLP (+1 h, n = 5; +3 h, n = 5; and +6 h, n = 6). (c) C57BL/6J 
mice were i.v. (n = 11) or intraperitoneally (n = 9) infused with 6 mg/kg CD6.
PD3 peptide or saline (n = 9) 1 h post CLP. In all cases, average percentage 
of survival was analyzed over time and compared with the saline-treated 
group using a log-rank t-test (n.s., not significant; *P < 0.05. **P < 0.01;  
and ***P < 0.001).
FigUre 5 | Comparative therapeutic effects of intravenous (i.v.) infused 
CD6-derived peptides on mouse survival following cecal ligation and 
puncture (CLP)-induced sepsis. C57BL/6J mice were i.v. infused with saline 
(n = 31) or single 6 mg/kg doses of unlabeled CD6 (PD1, n = 8; PD2, n = 16; 
PD3, n = 22) or DMBT-1/SAG (pbs1, n = 13) derived peptides 1 h post CLP 
induction. A sham group (n = 3) was included, which received saline. The 
average percent survival was analyzed over time for each group and 
compared to the saline-treated group using the long-rank t-test (**P < 0.01; 
***P < 0.001, ****P < 0.0001).
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models of septic shock (24). This also holds for septic mice 
simultaneously treated with CD6.PD3 and the broad-spectrum 
bactericidal antibiotic Imipenem/Cilastatin. As illustrated in 
Figure 8, the combined administration of CD6.PD3 (6 mg/kg i.v.) 
and Imipenem/Cilastatin (50  mg/kg/12  h i.p.) 1  h post CLP-
induced septic shock resulted in additive/synergistic effects on 
mice survival (90.9%), compared to either treatment individually 
(30.8 and 44.4%, respectively).
DiscUssiOn
Membrane-bound and soluble forms of the lymphocyte recep-
tor CD6 act as receptors for bacterial PAMPs of Gram-negative 
or Gram-positive origin (14, 23). The bacterial-binding proper-
ties of host receptors can be exploited as a source of alterna-
tive/adjunctive therapies for the prevention and/or treatment 
of severe infectious processes with little or no response to 
conventional antibiotic therapy (3), as is the case of the CD6 
receptor in proof of principle studies performed by our group. 
The prophylactic or therapeutic infusion of a single dose of 
rshCD6 increases survival of mice undergoing lethal septic 
shock following mono- or poly-microbial peritonitis (23, 24), 
concomitant with lower levels of circulating pro-inflammatory 
cytokines and lower bacterial loads. Importantly, rshCD6 infu-
sion shows additive effects when combined with a bactericidal 
antibiotic (Imipenem/Cilastatin) and displays efficacy against 
drug-resistant Gram-negative and Gram-positive strains 
(Colistin-resistant A. baumannii and MRSA) (23, 24). The 
latter results from CD6 specifically targeting LPS and LTA/
PGN, which are key pathogenic bacterial structures not easily 
amenable to antibiotic-induced mutation, as this would impact 
bacterial viability and/or pathogenicity.
In the present work, we have identified short (11-mer long) 
CD6-derived intradomain peptides retaining in vitro and in vivo 
bacterial-recognition properties of the native CD6 protein. 
Such sequences (CD6.PD1, CD6.PD2, and CD6.PD3) map 
at surface-accessible sites of the three SRCR domains of CD6 
and are homologous to the 11-mer consensus peptide (pbs1) 
identified in DMBT-1/SAG (10). While (i) similar homologous 
sequences from some SRCR-SF members possessing the minimal 
VEVLxxxxW motif do not bind to bacteria (10), and (ii) none 
of the CD6-derived peptides fully matched the consensus motif, 
all the three CD6-derived peptides interact with both LPS and 
LTA albeit with different Kd, and with varied in vitro and in vivo 
functional properties (e.g., bacterial agglutination or prevention 
of CLP-induced mortality). This is best illustrated by CD6.PD3, 
FigUre 8 | Additive effects of combined administration of CD6.PD3 and 
Imipenem/Cilastatin on mouse survival following cecal ligation and puncture 
(CLP)-induced sepsis. C57BL/6J mice were therapeutically infused 1 h post 
CLP with saline (n = 31), CD6.PD3 (6 mg/kg intravenous; n = 25), Imipenem/
Cilastatin (I/C, 50 mg/kg/12h intraperitoneal; n = 9), or a combination of the 
two later (n = 11). The average percent survival was analyzed over time for 
each group and compared to the I/C plus CD6.PD3 group using the 
long-rank t-test (*P < 0.05 and **P < 0.01).
FigUre 7 | Effect of CD6.PD3 therapeutic infusion on cytokine plasma 
levels and bacterial load following cecal ligation and puncture (CLP)-induced 
sepsis. (a) C57BL/6J mice were intravenous infused 1 h post CLP with 
saline (n = 7) or CD6.PD3 peptide (6 mg/kg; n = 9), and cytokine plasma 
levels were monitored by ELISA at different time points (4 and 20 h) 
thereafter. Data are expressed as mean ± SD. (B) Same mouse groups as in 
(a) were monitored for blood and spleen bacterial load at different time 
points (4 and/or 20 h) following CLP induction. Data are expressed as 
mean ± SD of colony-forming units (CFU)/mg (spleen) or CFU/μL (blood).  
In all cases, statistical differences were evaluated using a two-tailed  
Student t-test (*P < 0.05).
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which excelled in in  vitro functional assays, while exhibited 
lowest affinity for LPS and LTA. A plausible explanation arises 
from the hydrodynamic diameter of CD6-derived peptides in 
solution, in which CD6.PD3 shows higher self-aggregation 
values. A number of antimicrobial peptides (including SP-BN, 
cathelicidin LL-37, dermaseptin S9, and temporins B and L) 
have been reported to form aggregates (30, 33–35), suggesting 
a mechanistic connection between peptide aggregation and 
antimicrobial activity.
The CD6.PD3 peptide also provided better in  vivo results 
when assayed for therapeutical purposes in the mouse model 
CLP-induced septic shock compared with the other CD6-derived 
peptides (P  =  0.0405 for CD6.PD2 and P  <  0.0005 for CD6.
PD1) but not with the prototypical DMBT-1/SAG.pbs1 peptide 
(P  >  0.194). It should be noted in this regard that neither the 
DMBT-1/SAG.pbs1 nor the CD163p2 peptides have been tested 
before for their anti-bacterial efficacy in in vivo mouse models 
of infection. Another remarkable finding is CD6.PD3 peptide’s 
additive/synergistic effect on mice survival when coadministered 
with Imipenem/Cilastatin, a member of the carbapenem fam-
ily considered as first-choice treatment in critical care patients 
undergoing sepsis (36). Therefore, CD6.PD3 gathers most of the 
anti-bacterial properties of rshCD6, thus constituting a good 
cost-effective alternative to the latter, as well as a good adjunctive 
strategy to antibiotic therapy.
CD6.PD1 and CD6.PD2 high affinity (and also CD6.PD3) 
to LPS and LTA makes these peptides suitable candidates 
for new supportive non-antibiotic strategies against sepsis. 
One such possibility would be the adsorption of circulating 
bacterial toxins by CD6-derived peptides covalently coupled 
to a solid phase. Preliminary results obtained by incubat-
ing an endotoxin solution (50  UI/mL LPS) with Eupergit® 
beads coated with different CD6-derived peptides (CD6.
PD2 and CD6.PD3) or proteins (HSA, rshCD5, and rshCD6) 
for different periods of time support this approach (Figure 
S2 in Supplementary Material). CD6.PD2-, CD6.PD3-, and 
rshCD6-coated beads reduced endotoxin levels (as detected by 
LAL assays) compared to HSA- and rshCD5-coated controls. 
The use of CD6-derived peptides for extracorporeal hemop-
erfusion would deserve further exploration since it would 
have advantages over existing devices such as Polymyxin 
B-immobilized fiber blood-purification columns (37): (i) 
the reported affinity of the LPS/Polymixin B interaction (Kd 
100–900  nM, depending on the Gram-negative strain used) 
(38) is lower than that of CD6.PD1 and CD6.PD2 (Kd 3.5 ± 0.3 
and 35  ±  2  nM, respectively), and (ii) Polymixin B mainly 
binds to LPS, while CD6.PD1 and CD6.PD2 also bind LTA 
with affinities of Kd 0.39 ± 0.06 and 0.31 ± 0.04 nM, respec-
tively. The latter would support the use of those CD6-derived 
peptides in the case of Gram-positive infections, responsible 
for over 50% of sepsis (39).
In conclusion, the present findings that short (11-mer) 
peptide sequences can retain the bacterial-binding properties of 
the whole extracellular region of CD6 open cost-effective oppor-
tunities for developing new adjunctive alternatives to currently 
available sepsis treatment. The complex physiology of the sepsis 
response requires multi-disciplinary and simultaneously study 
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of the various time-dependent factors determining short- and 
long-term sepsis outcome.
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